WO2022080815A1 - 제미글립틴 및 다파글리플로진을 포함하는 경구용 복합제제, 및 이의 제조 방법 - Google Patents
제미글립틴 및 다파글리플로진을 포함하는 경구용 복합제제, 및 이의 제조 방법 Download PDFInfo
- Publication number
- WO2022080815A1 WO2022080815A1 PCT/KR2021/014013 KR2021014013W WO2022080815A1 WO 2022080815 A1 WO2022080815 A1 WO 2022080815A1 KR 2021014013 W KR2021014013 W KR 2021014013W WO 2022080815 A1 WO2022080815 A1 WO 2022080815A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diabetes
- treatment
- type
- acid
- pharmaceutically acceptable
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to an oral combination preparation for efficiently treating type 2 diabetes, and more particularly, as active ingredients, gemigliptin or a pharmaceutically acceptable salt thereof, and dapagliflozin or a pharmaceutically thereof acceptable salts, lactose and/or microcrystalline cellulose as bulking agents; disintegrant; And it relates to an oral combination formulation for the treatment of type 2 diabetes comprising a lubricant, and a manufacturing method thereof.
- the International Diabetes Federation estimated that there were 366 million people with diabetes worldwide. It was reported that 80% of them are concentrated in developing countries, and about 36% belong to the Western Pacific region including Korea. However, considering about 183 million people who are currently diabetic but not diagnosed with diabetes, the actual number of diabetic patients worldwide is expected to exceed 549 million, and in 2011 alone, 4.6 It was reported that 100,000 people died due to diabetes.
- Type 1 diabetes is a result of the destruction of pancreatic beta cells ( ⁇ -cells), which is a serious disease that can lead to ketosis if not treated. It usually develops in childhood, but sometimes it can also develop in adults who are not obese and whose first symptoms of hyperglycemia appear later in life.
- Type 2 diabetes which is currently on the rise, accounts for 90 to 95% of all diabetes, and it is a complex disease whose mechanism is not clearly elucidated. Symptoms are not severe and appear in various forms, which are complexly involved in beta cell dysfunction, peripheral insulin resistance, and hepatic glucose metabolism abnormalities.
- Existing oral drugs used for the treatment of diabetes include insulin-secreting agents such as sulfonylureas and meglitinides, biguanides, thiazolidinediones, and alpha -Glucosidase inhibitors ( ⁇ -glucosidase inhibitors) can be broadly divided into 4 groups.
- Sulfonylureas and biguanides have been used for a long time as a treatment for type 2 diabetes.
- sulfonylurea promotes insulin secretion from beta cells, but eventually the beta cell function gradually decreases, leading to other drugs or insulin treatment.
- Metformin is a representative drug belonging to the biguanide, and it is a safe drug with few side effects of hypoglycemia and is widely used as the first drug prescribed for the treatment of type 2 diabetes. Because type 2 diabetes is a progressive disease, long-term treatment cannot control blood sugar sufficiently, and combination therapy is required within a few years after diagnosis.
- a pharmaceutical comprising dapagliflozin and linagliptin as active ingredients, a SGLT-2 inhibitor, and a DPP-IV inhibitor
- the composition is disclosed.
- the present invention alleviates the side effects of the existing single agent and at the same time increases the bioavailability and stability of the active ingredient to effectively treat type 2 diabetes. Its technical task is to provide a combination formulation that can be
- another technical task of the present invention is to provide a method capable of manufacturing a complex formulation with high productivity while increasing the stability of the active ingredient.
- the present invention provides an active ingredient, including gemigliptin or a pharmaceutically acceptable salt thereof, and dapagliflozin or a pharmaceutically acceptable salt thereof; lactose and/or microcrystalline cellulose as bulking agents; disintegrant; And it provides an oral combination formulation for the treatment of type 2 diabetes comprising a lubricant.
- the present invention provides i) as an active ingredient, gemigliptin or a pharmaceutically acceptable salt thereof and dapagliflozin or a pharmaceutically acceptable salt thereof; lactose and/or microcrystalline cellulose as bulking agents; and sieving the disintegrant and then mixing; ii) It provides a method for preparing an oral combination formulation for the treatment of type 2 diabetes, comprising adding a lubricant to the mixture obtained in step (i), mixing, and then tableting.
- an oral combination formulation for the treatment of type 2 diabetes comprising a lubricant and a lubricant.
- Gemigliptin is a relatively recently developed potent and selective dipeptidyl peptidase IV (DPP-IV) inhibitor, and the DPP-IV inhibitor is GLP-1 (glucagon-like pepetide-1). It is a drug designed to inhibit degradation by IV. GLP-1 is an incretin that promotes insulin secretion from beta cells, increases glucose utilization in peripheral tissues, suppresses glucagon secretion in alpha cells, and reduces glucose production in the liver.
- DPP-IV dipeptidyl peptidase IV
- gemigliptin various types of pharmaceutically acceptable salts may be used.
- pharmaceutically acceptable salts of gemigliptin include, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, acetic acid, trifluoroacetic acid, citric acid, formic acid, maleic acid, oxalic acid (oxalic acid), succinic acid, benzoic acid, Tartaric acid, fumaric acid, manderic acid, ascorbic acid, malic acid, methanesulfonic acid, and the like, and preferably tartaric acid salt 1.5 hydrate may be used.
- Dapagliflozin is a sodium glucose co-transpoerter-2 (SGLT-2) inhibitor that inhibits glucose reabsorption by inhibiting SGLT-2 in the renal tubule. Glucose can be excreted in the urine to suppress the rise in blood sugar.
- dapagliflozin may be amorphous and in particulate form.
- the lactose as the bulking agent may be lactose anhydrous or lactose hydrate.
- the disintegrant may be croscarmellose sodium or crospovidone (cross-linked polyvinyl N-pyrrolidone).
- the lubricant may be sodium stearyl fumarate.
- the oral combination preparation for the treatment of type 2 diabetes contains 20 to 60% by weight of active ingredient, gemigliptin or a pharmaceutically acceptable salt thereof, and dapagliflozin or a drug thereof. It may contain a scientifically acceptable salt, 20 to 70% by weight of a bulking agent, lactose and/or microcrystalline cellulose, 0.5 to 15% by weight of a disintegrant, and 0.2 to 15% by weight of a lubricant.
- the oral combination formulation for the treatment of type 2 diabetes is 30 to 50% by weight of active ingredient, gemigliptin or a pharmaceutically acceptable salt thereof, and dapagliflozin or a drug thereof It may contain a scientifically acceptable salt, 30 to 65% by weight of lactose and/or microcrystalline cellulose as a bulking agent, 1 to 10% by weight of a disintegrant, and 0.5 to 10% by weight of a lubricant.
- the oral combination formulation for the treatment of type 2 diabetes is based on the free form of gemigliptin or a pharmaceutically acceptable salt thereof and dapagliflozin or a pharmaceutically acceptable salt thereof.
- As 2 to 10: 1 may be included in a weight ratio.
- the oral combination formulation for the treatment of type 2 diabetes is based on the free form of gemigliptin or a pharmaceutically acceptable salt thereof and dapagliflozin or a pharmaceutically acceptable salt thereof.
- 3 to 7: 1 may be included in a weight ratio.
- the oral combination formulation for the treatment of type 2 diabetes is based on the free form of gemigliptin or a pharmaceutically acceptable salt thereof and dapagliflozin or a pharmaceutically acceptable salt thereof. As such, it may be included in a weight ratio of 5: 1.
- the oral combination formulation for the treatment of type 2 diabetes according to the present invention may contain 50 mg of gemigliptin and 10 mg of dapagliflozin.
- the oral combination formulation for the treatment of type 2 diabetes may further include a coating agent.
- the usable coating agent is a coating agent commonly used in the art, for example, polyvinylpyrrolidone, copovidone, Opadry series, Eudragit series, etc. may include, but is not limited to.
- the coating agent may be Opadry.
- the oral combination preparation for the treatment of type 2 diabetes may be in the form of granules, capsules or tablets.
- a method for preparing an oral combination preparation for the treatment of type 2 diabetes comprising adding a lubricant to the mixture obtained in step (i), mixing, and then tableting.
- the lactose may be anhydrous lactose or lactose hydrate.
- the disintegrant may be croscarmellose sodium or crospovidone.
- the lubricant may be sodium stearyl fumarate.
- a synergistic combination of drugs having different mechanisms of action It is possible to alleviate the side effects of a single agent and to efficiently treat type 2 diabetes due to the high bioavailability and high stability of the active ingredient due to the high dissolution rate of the active ingredient.
- the manufacturing method according to the present invention can provide a combination formulation with increased stability of the active ingredient with high productivity by using a direct manufacturing method.
- Example 1 is a graph showing the results of measuring the dissolution rate of gemigliptin in the tablet of Example 16 (Zemiglo tablet: gemigliptin 50 mg tablet).
- Figure 2 is a graph showing the result of measuring the dissolution rate of dapagliflozin in the tablet of Example 16 (Posi family: dapagliflozin 10 mg tablet).
- composition of Table 1 below 68.9 mg of gemigliptin tartrate (50 mg as gemigliptin), 10 mg of dapagliflozin, extender, and disintegrant were sieved through cornmeal and mixed, and then a lubricant was added. final mixing. The final mixture was tableted to prepare a single-layer tablet.
- Tablets containing gemigliptin tartrate, dapagliflozin, microcrystalline cellulose, anhydrous lactose, croscarmellose sodium and sodium stearyl fumarate in various contents were prepared according to the composition of Examples 1 to 4 and It was prepared in the same way.
- Example 16 The stability of the tablet prepared in Example 16 was measured in the same manner as in Experimental Example 1, and the results are shown in Tables 9 and 10, respectively, and the dissolution rate was measured in the same manner as in Experimental Example 3 for pH 1.2 solution, pH 4.5 solution, and pH. It was measured in 6.8 liquid and water, and the results are shown in FIGS. 1 and 2 .
- Example 16 provided stability to gemigliptin and dapagliflozin, and the dissolution rate was comparable to each individual formulation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (18)
- 유효성분으로 제미글립틴 또는 이의 약제학적으로 허용가능한 염 및 다파글리플로진 또는 이의 약제학적으로 허용가능한 염; 증량제로 유당 및/또는 미결정 셀룰로오스; 붕해제; 및 활택제를 포함하는 제2형 당뇨병 치료용 경구용 복합제제.
- 제1항에 있어서, 상기 제미글립틴의 약제학적으로 허용가능한 염이 염산, 브롬산, 인산, 황산, 아세트산, 트리플루오로아세트산, 구연산, 포름산, 말레인산, 수산, 호박산, 벤조인산, 타르타르산, 푸말산, 만데린산, 아스코르빈산, 말린산 및 메탄술폰산으로 이루어지는 그룹으로부터 선택되는 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제.
- 제2항에 있어서, 상기 제미글립틴의 약제학적으로 허용가능한 염이 타르타르산염인 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제.
- 제1항에 있어서, 상기 다파글리플로진이 다파글리플로진 무정형인 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제.
- 제1항에 있어서, 상기 유당이 무수유당 또는 유당 수화물인 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제.
- 제1항에 있어서, 상기 붕해제가 크로스카르멜로오스나트륨 또는 크로스포비돈인 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제.
- 제1항에 있어서, 상기 활택제가 스테아릴푸마르산나트륨인 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제.
- 제1항에 있어서, 20 내지 60 중량%의 유효성분, 20 내지 70 중량%의 증량제, 0.5 내지 15 중량%의 붕해제 및 0.2 내지 15 중량%의 활택제를 포함하는 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제.
- 제8항에 있어서, 30 내지 50 중량%의 유효성분, 30 내지 65 중량%의 증량제, 1 내지 10 중량%의 붕해제 및 0.5 내지 10 중량%의 활택제를 포함하는 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제.
- 제1항에 있어서, 상기 제미글립틴 또는 이의 약제학적으로 허용가능한 염 및 다파글리플로진 또는 이의 약제학적으로 허용가능한 염을 유리형 기준으로 2 내지 10 : 1의 중량비로 포함하는 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제.
- 제10항에 있어서, 상기 제미글립틴 또는 이의 약제학적으로 허용가능한 염 및 다파글리플로진 또는 이의 약제학적으로 허용가능한 염을 유리형 기준으로 5 : 1의 중량비로 포함하는 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제.
- 제1항에 있어서, 코팅제를 추가로 포함하는 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제.
- 제12항에 있어서, 상기 코팅제가 오파드라이인 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제.
- 제1항에 있어서, 과립제, 캡슐제 또는 정제 형태인 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제.
- i) 유효성분으로 제미글립틴 또는 이의 약제학적으로 허용가능한 염 및 다파글리플로진 또는 이의 약제학적으로 허용가능한 염; 증량제로 유당 및/또는 미결정 셀룰로오스; 및 붕해제를 체과한 다음 혼합하고;ii) 단계 (i)에서 얻어진 혼합물에 활택제를 첨가하고 혼합한 다음 타정하는 것을 포함하는 제1항에 정의된 제2형 당뇨병 치료용 경구용 복합제제의 제조 방법.
- 제15항에 있어서, 상기 유당이 무수유당 또는 유당 수화물인 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제의 제조 방법.
- 제15항에 있어서, 상기 붕해제가 크로스카멜로오스나트륨 또는 크로스포비돈인 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제의 제조 방법.
- 제15항에 있어서, 상기 활택제가 스테아릴푸마르산나트륨인 것을 특징으로 하는 제2형 당뇨병 치료용 경구용 복합제제의 제조 방법.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2023004218A MX2023004218A (es) | 2020-10-13 | 2021-10-12 | Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma. |
CR20230161A CR20230161A (es) | 2020-10-13 | 2021-10-12 | Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación para la misma |
PE2023001386A PE20231943A1 (es) | 2020-10-13 | 2021-10-12 | Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma |
DO2023000071A DOP2023000071A (es) | 2020-10-13 | 2023-04-12 | Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación para la misma |
CONC2023/0006028A CO2023006028A2 (es) | 2020-10-13 | 2023-05-11 | Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación para la misma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200131868 | 2020-10-13 | ||
KR10-2020-0131868 | 2020-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022080815A1 true WO2022080815A1 (ko) | 2022-04-21 |
Family
ID=81208465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/014013 WO2022080815A1 (ko) | 2020-10-13 | 2021-10-12 | 제미글립틴 및 다파글리플로진을 포함하는 경구용 복합제제, 및 이의 제조 방법 |
Country Status (10)
Country | Link |
---|---|
KR (1) | KR20220048952A (ko) |
CL (1) | CL2023001014A1 (ko) |
CO (1) | CO2023006028A2 (ko) |
CR (1) | CR20230161A (ko) |
DO (1) | DOP2023000071A (ko) |
EC (1) | ECSP23027106A (ko) |
MX (1) | MX2023004218A (ko) |
PE (1) | PE20231943A1 (ko) |
TW (1) | TWI826841B (ko) |
WO (1) | WO2022080815A1 (ko) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180058510A (ko) * | 2016-11-24 | 2018-06-01 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 약제학적 제제 |
KR20180078762A (ko) * | 2016-12-30 | 2018-07-10 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물 |
KR20180079176A (ko) * | 2016-12-30 | 2018-07-10 | 한미약품 주식회사 | 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제 |
KR20190130432A (ko) * | 2018-05-14 | 2019-11-22 | 씨제이헬스케어 주식회사 | Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물 |
-
2021
- 2021-10-12 WO PCT/KR2021/014013 patent/WO2022080815A1/ko active Application Filing
- 2021-10-12 KR KR1020210134776A patent/KR20220048952A/ko not_active Application Discontinuation
- 2021-10-12 PE PE2023001386A patent/PE20231943A1/es unknown
- 2021-10-12 CR CR20230161A patent/CR20230161A/es unknown
- 2021-10-12 MX MX2023004218A patent/MX2023004218A/es unknown
- 2021-10-13 TW TW110138009A patent/TWI826841B/zh active
-
2023
- 2023-04-06 CL CL2023001014A patent/CL2023001014A1/es unknown
- 2023-04-12 DO DO2023000071A patent/DOP2023000071A/es unknown
- 2023-04-13 EC ECSENADI202327106A patent/ECSP23027106A/es unknown
- 2023-05-11 CO CONC2023/0006028A patent/CO2023006028A2/es unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180058510A (ko) * | 2016-11-24 | 2018-06-01 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 약제학적 제제 |
KR20180078762A (ko) * | 2016-12-30 | 2018-07-10 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물 |
KR20180079176A (ko) * | 2016-12-30 | 2018-07-10 | 한미약품 주식회사 | 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제 |
KR20190130432A (ko) * | 2018-05-14 | 2019-11-22 | 씨제이헬스케어 주식회사 | Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물 |
Non-Patent Citations (1)
Title |
---|
KWAK SOO HEON, HWANG YOU‐CHEOL, WON JONG CHUL, BAE JI CHEOL, KIM HYUN JIN, SUH SUNGHWAN, LEE EUN YOUNG, LEE SUBIN, KIM SANG‐YONG, : "Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open‐label, active‐controlled, 12‐week study (STABLE II study)", DIABETES, OBESITY AND METABOLISM, BLACKWELL SCIENCE, GB, vol. 22, no. 2, 1 February 2020 (2020-02-01), GB , pages 173 - 181, XP055921788, ISSN: 1462-8902, DOI: 10.1111/dom.13882 * |
Also Published As
Publication number | Publication date |
---|---|
PE20231943A1 (es) | 2023-12-05 |
CL2023001014A1 (es) | 2023-12-11 |
KR20220048952A (ko) | 2022-04-20 |
MX2023004218A (es) | 2023-04-21 |
ECSP23027106A (es) | 2023-05-31 |
DOP2023000071A (es) | 2023-07-09 |
TWI826841B (zh) | 2023-12-21 |
CR20230161A (es) | 2023-09-21 |
CO2023006028A2 (es) | 2023-07-10 |
TW202228701A (zh) | 2022-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018124497A1 (ko) | 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제 | |
KR101697800B1 (ko) | 니타족사니드의 서방성 제약 제형 | |
US20110311594A1 (en) | Controlled release compositions with reduced food effect | |
WO2010137855A9 (en) | Multi-layer tablet comprising effervescent layer | |
KR101526825B1 (ko) | 당뇨병 치료용 약제학적 조성물 | |
WO2019147094A1 (en) | Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate | |
WO2019059557A2 (ko) | Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물 | |
KR20100015685A (ko) | 인슐린 분비 강화를 위한 라놀라진 | |
WO2014058188A1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
US20220184070A1 (en) | Low-dose triple combination formulation | |
AU2022266499A1 (en) | Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor | |
WO2022080815A1 (ko) | 제미글립틴 및 다파글리플로진을 포함하는 경구용 복합제제, 및 이의 제조 방법 | |
WO2018124468A1 (ko) | 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물 | |
WO2020171404A1 (ko) | 약학 조성물 | |
WO2020096328A1 (ko) | 시클로-히스프로를 유효성분으로 포함하는 비만 예방 또는 치료용 약제학적 조성물 | |
WO2020050677A1 (ko) | 안정성이 향상된 의약 조성물 | |
KR102633770B1 (ko) | 제2형 당뇨병 치료용 복합제제 | |
EP4161525A1 (en) | The process for the preparation of a film coated tablet comprising linagliptin and metformin | |
WO2022034944A1 (ko) | 제2형 당뇨병 치료용 복합제제 | |
WO2021133046A1 (ko) | 메트포르민 서방성 제제 및 이의 제조 방법 | |
WO2013032206A1 (ko) | 이토프라이드 염산염을 함유하는 제어 방출성 경구 제제의 조성물 및 그의 제조방법 | |
WO2020091406A1 (ko) | 제2형 당뇨병 치료용 약제학적 조성물 | |
WO2019124860A1 (ko) | 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제 | |
WO2024043358A1 (ko) | 에보글립틴 및 메트포르민을 포함하는 경구용 복합제제 및 그의 제조방법 | |
WO2022220636A1 (ko) | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 경구용 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21880462 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023006640 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112023006640 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230410 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21880462 Country of ref document: EP Kind code of ref document: A1 |